238 related articles for article (PubMed ID: 17851225)
1. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
[TBL] [Abstract][Full Text] [Related]
2. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.
Sohn JW; Lee SY; Lee SJ; Kim EJ; Cha SI; Kim CH; Lee JT; Jung TH; Park JY
Jpn J Clin Oncol; 2006 Mar; 36(3):137-41. PubMed ID: 16478794
[TBL] [Abstract][Full Text] [Related]
3. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
Pan JH; Han JX; Wu JM; Huang HN; Yu QZ; Sheng LJ
Respiration; 2009; 78(1):49-55. PubMed ID: 18812689
[TBL] [Abstract][Full Text] [Related]
4. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN
Acta Oncol; 2007; 46(3):361-6. PubMed ID: 17450472
[TBL] [Abstract][Full Text] [Related]
5. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
[TBL] [Abstract][Full Text] [Related]
7. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
Zhu LB; Xu Q; Hong CY; Yue Z; Zhang Y; Ye HN; Yuan Y
Anticancer Drugs; 2010 Aug; 21(7):669-73. PubMed ID: 20571354
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
10. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
Chen YM; Perng RP; Shih JF; Whang-Peng J
Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
[TBL] [Abstract][Full Text] [Related]
12. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
[TBL] [Abstract][Full Text] [Related]
15. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
Johne A; Köpke K; Gerloff T; Mai I; Rietbrock S; Meisel C; Hoffmeyer S; Kerb R; Fromm MF; Brinkmann U; Eichelbaum M; Brockmöller J; Cascorbi I; Roots I
Clin Pharmacol Ther; 2002 Nov; 72(5):584-94. PubMed ID: 12426522
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
20. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
